A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non–muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14
Titel:
A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non–muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14
Auteur:
Rentsch, Cyrill A. Thalmann, George N. Lucca, Ilaria Kwiatkowski, Maciej Wirth, Grégory J. Strebel, Räto T. Engeler, Daniel Pedrazzini, Augusto Hüttenbrink, Clemens Schultze-Seemann, Wolfgang Torpai, Raimund Bubendorf, Lukas Wicki, Andreas Roth, Beat Bosshard, Piet Püschel, Heike Boll, Daniel T. Hefermehl, Lukas Roghmann, Florian Gierth, Michael Ribi, Karin Schäfer, Simon Hayoz, Stefanie